Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 furnished disclosure only, with liability protections under Exchange Act Section 18 and Securities Act Sections 11 and 12(a)(2).
RIGEL PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 furnished disclosure only, with liability protections under Exchange Act Section 18 and Securities Act Sections 11 and 12(a)(2)
- No operating results or financial figures included in the provided text
- Accompanying exhibit excluded from incorporation by reference into future SEC filings
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $58.8M, up from $53.3M, led by product sales of $54.9M, up 26%
- TAVALISSE sales $37.3M, up 31%; REZLIDHIA $8.0M, up 31%; GAVRETO $9.6M, up 7%
- Net income $8.7M, or $0.44 diluted EPS, versus $11.4M and $0.63 in Q1 2025
- 2026 guidance reaffirmed: revenue $275–$290M, including product sales of $255–$265M and positive full-year net income
- Lilly collaboration termination effective June 15, 2026; Rigel replaced its term loan with a $40.0M revolver and drew $8.0M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RIGEL PHARMACEUTICALS INC 8-K filings
Get the next RIGL 8-K as it lands
Follow RIGL for push alerts, or ask the research agent what this filing means.